The ‘as a service’ (AAS) model transformed the IT industry – making innovative technologies accessible to businesses without the high price point that would previously have been a barrier.<
Rising payment percentages under the Voluntary Scheme for Branded Medicines Pricing and Access (VPAS) have been criticised despite (some in) the industry knowing that payment percentages in
The advancements made in drug development over the last decade have seen the arrival of a number of treatments that offer one-time cures and more effective therapies for conditions in small
As part of our Women in Pharma series, where we talk to leading figures in the life sciences, we hear from Şeyda Atadan Memiş, recently appointed general manager for Takeda UK and